Your browser doesn't support javascript.
How a Community Approach Can Drive Pharmacovigilance Activities in Low-Resource Settings during a Public Health Emergency: Lessons from COVID-19: An International Journal of Medical Toxicology and Drug Experience
Drug Safety ; 45(10):1191, 2022.
Article in English | ProQuest Central | ID: covidwho-2046981
ABSTRACT

Introduction:

Undertaking effective drug safety monitoring can be particularly challenging in low-resource settings due to a lack of infrastructure, weak regulatory systems and poor access to training and education [1]. Given the continued impact the COVID-19 pandemic is having upon health systems globally, it is essential to ensure that pharmacovigilance systems in these vulnerable settings have the capacity to address both the exacerbated pre-existing and novel challenges that they now face [2]. This project seeks to harness the membership of an online pharmacovigilance platform, globalpharmacovigilance.org (GPV) to work together in a 'community of practice' (CoP) on specific challenges facing pharmacovigilance during the pandemic [3, 4].

Objective:

To gather consensus on pharmacovigilance priorities in low-resource settings during the COVID-19 pandemic and provide resources to address them using a CoP model.

Methods:

This project has built on a consensus-gathering methodology developed by The Global Health Network that has been implemented successfully during the pandemic to address wider COVID-19 research priorities. An online survey of GPV members was used to identify highly-ranked areas for pharmacovigilance improvement in low-resource settings during the pandemic. A virtual workshop was then hosted to invite further discussion on the survey results and reach consensus on the highest priorities. Members of the CoP were next invited to form virtual working groups, each focussing on one of the top 3 priorities identified. These groups are being supported by GPV to work together and facilitate the development (or provision, if pre-existing) of pharmacovigilance resources to address the priorities identified.

Results:

Of the 43 pharmacovigilance 'themes' that were presented to the CoP membership in the initial survey, 3 topics were identified as the highest priorities at that point in the COVID-19 pandemic, where support, training and guidance are needed;'The safety of COVID-19 vaccination in pregnancy', 'The safety of COVID-19 vaccination in children/adolescents' and 'Analysis of COVID-19 vaccine safety data'. As of May 2022, the number of GPV members interested in involvement in working groups addressing these themes are 207, 206, and 284 respectively. Initial group meetings took place in April 2022 and discussions are ongoing as to how to take group activities forward and address the priorities identified.

Conclusion:

A CoP model represents an effective method of consensus gathering amongst pharmacovigilance stakeholders at a global level, and allows rapid identification of healthcare priorities during public health emergencies. It is anticipated that working groups outputs will include the provision of resources designed to address the priorities identified.
Keywords
Search on Google
Collection: Databases of international organizations Database: ProQuest Central Language: English Journal: Drug Safety Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: ProQuest Central Language: English Journal: Drug Safety Year: 2022 Document Type: Article